Dr. Beena Pillai Takes the Helm as Director of India's Premier Biotech Institute
Synopsis
Key Takeaways
Thiruvananthapuram, April 16 (NationPress) In a significant shift in leadership at one of India's leading biotechnology institutes, the Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB) has appointed the esteemed scientist Dr. Beena Pillai as its new Director.
This appointment, sanctioned by the Appointments Committee of the Union Cabinet, will span a term of five years.
Operating under the auspices of the Biotechnology Research and Innovation Council within the Department of Biotechnology, BRIC-RGCB is pivotal in enhancing research related to disease biology, translational sciences, and technological advancements.
The institute has been instrumental in linking fundamental research with practical clinical and industrial applications, making this leadership transition crucial for India's overarching biotechnology goals.
Dr. Pillai takes over from Prof. Chandrabhas Narayana, who concluded his tenure in September of the previous year, and assumes leadership at a time when the institute is prepared to expand into impactful domains.
Currently serving as a Chief Scientist at the CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Dr. Pillai is globally recognized for her contributions to RNA biology and neuronal development.
Her research centers on the significance of RNA during early development, neurogenesis, behavior, and susceptibility to diseases, which includes identifying microRNA markers in human ailments.
A native of Kalady, she earned her B.Sc from Ramnarain Ruia College in Mumbai and completed an integrated MS-PhD at the Indian Institute of Science.
Following that, she joined CSIR-IGIB, where she established a robust research program in genomics and molecular biology.
Her scientific achievements have been honored with numerous accolades, such as the National Bioscience Award, the INSA Young Scientist Award, and the CSIR Young Scientist Award in Biological Sciences.
Under her guidance, BRIC-RGCB is anticipated to expedite pivotal national projects, including the establishment of a cGMP-compliant facility, a bio-manufacturing center, and an oncology referral hospital.
This appointment is broadly viewed as a significant step towards fortifying India's research-to-innovation continuum, with the RGCB scientific community expressing optimism for a renewed commitment to pioneering science.